{"id":"secukinumab-auto-injector","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Nasopharyngitis"},{"rate":"5-10","effect":"Upper respiratory tract infection"},{"rate":"3-5","effect":"Diarrhea"},{"rate":"2-5","effect":"Injection site reactions"},{"rate":"1-3","effect":"Candida infections"}]},"_chembl":{"chemblId":"CHEMBL1743068","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By binding to and neutralizing IL-17A, secukinumab inhibits the IL-17 signaling pathway, which plays a central role in the pathogenesis of autoimmune and inflammatory conditions. This reduces the recruitment and activation of immune cells at sites of inflammation, thereby suppressing the inflammatory cascade. The auto-injector formulation provides patients with a convenient subcutaneous delivery option.","oneSentence":"Secukinumab is a monoclonal antibody that blocks interleukin-17A (IL-17A), a key inflammatory cytokine involved in immune-mediated diseases.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:07:11.748Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe plaque psoriasis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Non-radiographic axial spondyloarthritis"}]},"trialDetails":[{"nctId":"NCT04535999","phase":"PHASE4","title":"Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2022-02-07","conditions":"Psoriasis","enrollment":16},{"nctId":"NCT03589885","phase":"PHASE3","title":"Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-19","conditions":"Plaque Psoriasis","enrollment":122},{"nctId":"NCT04414605","phase":"EARLY_PHASE1","title":"Oral Chinese Herbal Medicine Concurrent With Secukinumab for Severe Plaque Psoriasis","status":"UNKNOWN","sponsor":"Guangdong Provincial Hospital of Traditional Chinese Medicine","startDate":"2020-06-04","conditions":"Psoriasis","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cosentyx"],"phase":"marketed","status":"active","brandName":"Secukinumab Auto-Injector","genericName":"Secukinumab Auto-Injector","companyName":"University of Pennsylvania","companyId":"university-of-pennsylvania","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Secukinumab Auto-Injector is a medication used to treat conditions such as Psoriasis and Plaque Psoriasis. It works by inhibiting Interleukin 17A, a protein involved in inflammation, through its mechanism as an Interleukin 17A inhibitor.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2015-01-14T00:00:00.000Z","mah":"Novartis Europharm Limited","brand_name_local":"Cosentyx","application_number":"EMEA/H/C/003729"}],"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}